Samples influence physician behavior
A new study published in the Journal of Internal Medicine (vol. 15, no. 7) shows that samples handed out by pharmaceutical sales representatives may influence doctors to prescribe drugs they wouldn't have otherwise.
A new study published in the Journal of Internal Medicine (vol. 15, no. 7) shows that samples handed out by pharmaceutical sales representatives may influence doctors to prescribe drugs they wouldn't have otherwise.
The cross-sectional survey of 154 general medicine and family physicians was conducted to determine why and under what circumstances physicians dispense drug samples, if drug samples lead doctors to use medications other than those they normally prescribe and what type of physicians use drug samples.
Of a total of 131 respondents out of 154 surveyed, 17% of physicians reported that they would dispense a drug sample to an insured woman with an uncomplicated lower urinary tract infection. Of those, 95% reported that they would dispense a sample that differed from their normal drug of choice. Twenty-seven percent of respondents said they would dispense a drug sample to an uninsured man with hypertension. Of those, 91% said they would sample a drug that differed from their normal drug of choice. And, when presented with an uninsured woman with depression, 82% of respondents reported they would dispense a drug sample; of those, 49% said they would dispense a drug that differed from their drug of choice.
According to the survey, avoiding cost to the patient was the most frequent reason given for dispensing a drug sample. PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
